社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
yvo92
IP属地：未知
+关注
帖子 · 11
帖子 · 11
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
yvo92
yvo92
·
2021-07-01
Nice
非常抱歉，此主贴已删除
看
1,396
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-25
Good
非常抱歉，此主贴已删除
看
1,497
回复
评论
点赞
1
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-23
Good
非常抱歉，此主贴已删除
看
1,618
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-21
Nice
Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme盘前交易涨超6%</blockquote>
(June 21) Orphazyme rose more than 6% in premarket trading. What happened Shares of Orphazyme, a c
Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme盘前交易涨超6%</blockquote>
看
1,668
回复
2
点赞
2
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-18
Wow
非常抱歉，此主贴已删除
看
2,929
回复
评论
点赞
2
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-18
Good
非常抱歉，此主贴已删除
看
1,368
回复
评论
点赞
5
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-17
Bad
Musk-Touted CureVac Loses 49% of Value After Vaccine Setback<blockquote>马斯克吹捧的CureVac在疫苗受挫后损失了49%的价值</blockquote>
Company plunges After Covid Shot Falls Short With 47% Efficacy Effectiveness is far below that seen
Musk-Touted CureVac Loses 49% of Value After Vaccine Setback<blockquote>马斯克吹捧的CureVac在疫苗受挫后损失了49%的价值</blockquote>
看
1,756
回复
评论
点赞
4
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-16
Nice
非常抱歉，此主贴已删除
看
1,443
回复
1
点赞
1
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-15
Hi everybody
看
1,488
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
yvo92
yvo92
·
2021-06-15
Nice
非常抱歉，此主贴已删除
看
1,034
回复
评论
点赞
2
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3575604969719218","uuid":"3575604969719218","gmtCreate":1612787974300,"gmtModify":1612787974300,"name":"yvo92","pinyin":"yvo92","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":158368602,"gmtCreate":1625130308506,"gmtModify":1633944469275,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575604969719218","idStr":"3575604969719218"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/158368602","repostId":"1198389317","repostType":4,"isVote":1,"tweetType":1,"viewCount":1396,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122559363,"gmtCreate":1624628563952,"gmtModify":1633950344693,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575604969719218","idStr":"3575604969719218"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/122559363","repostId":"2146023477","repostType":4,"isVote":1,"tweetType":1,"viewCount":1497,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123681976,"gmtCreate":1624420771695,"gmtModify":1634006355071,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575604969719218","idStr":"3575604969719218"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123681976","repostId":"1116451605","repostType":4,"isVote":1,"tweetType":1,"viewCount":1618,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167562823,"gmtCreate":1624278271462,"gmtModify":1634008539969,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575604969719218","idStr":"3575604969719218"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/167562823","repostId":"1184501396","repostType":4,"repost":{"id":"1184501396","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624267024,"share":"https://www.laohu8.com/m/news/1184501396?lang=zh_CN&edition=full","pubTime":"2021-06-21 17:17","market":"us","language":"en","title":"Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme盘前交易涨超6%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1184501396","media":"Tiger Newspress","summary":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a c","content":"<p>(June 21) Orphazyme rose more than 6% in premarket trading. </p><p><blockquote>（6月21日）Orphazyme盘前交易涨超6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> Shares of <b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.</p><p><blockquote>本公司之股份<b>Orphazyme</b>一家处于临床阶段的生物制药公司在食品和药物管理局(FDA)拒绝批准该公司主要候选药物的申请后受到了打击。投资者现在不确定该生物技术公司何时可以获得批准的产品出售，截至中午12点12分，该股股价下跌44.4%。上周五美国东部时间。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p><p><blockquote>FDA去年9月开始审查Orphazyme的主要候选药物arimoclomol的申请，作为一种罕见但危及生命的疾病（称为C型奈曼-皮克病(NPC)）的潜在治疗方法。本月早些时候，由于预期绿灯从未到来，Orphazymes的股价飙升超过200%。</blockquote></p><p> Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p><p><blockquote>该机构没有对arimoclomol做出批准决定，而是以完整回复信(CRL)的形式要求提供更多信息。这让许多刚接触复杂的药物开发领域并预计会出现大规模轧空的投资者感到震惊。</blockquote></p><p> Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p><p><blockquote>许多机构投资者对Orphazyme做空，因为其主要候选药物未能达到支持该申请的关键研究的主要终点。Arimoclomol也未能改善患者在FDA特别要求的次要终点上的评分。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p><p><blockquote>据Orphazyme称，该公司需要进一步证实arimoclomol几乎达到的主要终点的有效性。为了让FDA满意，该公司很可能必须进行一项新的关键研究。</blockquote></p><p> Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p><p><blockquote>一些股东仍然希望欧洲药品管理局不会像FDA那样严格。虽然FDA的欧洲同事过去对罕见疾病的治疗更加宽容，但在产生一些令人信服的临床试验结果之前，arimoclomol可能不会向前推进。</blockquote></p><p> Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p><p><blockquote>尽管缺乏明确的前进道路，但这家总部位于丹麦的公司仍然拥有相当大的市值，按最近的价格计算超过5亿美元。非理性的预期可能会使其居高不下，但对于Orphazyme的任何临床阶段生物技术来说，这都太高了。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme rose more than 6% in premarket trading<blockquote>Orphazyme盘前交易涨超6%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme rose more than 6% in premarket trading<blockquote>Orphazyme盘前交易涨超6%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-06-21 17:17</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>(June 21) Orphazyme rose more than 6% in premarket trading. </p><p><blockquote>（6月21日）Orphazyme盘前交易涨超6%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/a1e2eb27cc68ce74ddd21a64a64634cf\" tg-width=\"719\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>What happened</b></p><p><blockquote><b>发生了什么</b></blockquote></p><p> Shares of <b>Orphazyme</b>, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.</p><p><blockquote>本公司之股份<b>Orphazyme</b>一家处于临床阶段的生物制药公司在食品和药物管理局(FDA)拒绝批准该公司主要候选药物的申请后受到了打击。投资者现在不确定该生物技术公司何时可以获得批准的产品出售，截至中午12点12分，该股股价下跌44.4%。上周五美国东部时间。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> The FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.</p><p><blockquote>FDA去年9月开始审查Orphazyme的主要候选药物arimoclomol的申请，作为一种罕见但危及生命的疾病（称为C型奈曼-皮克病(NPC)）的潜在治疗方法。本月早些时候，由于预期绿灯从未到来，Orphazymes的股价飙升超过200%。</blockquote></p><p> Instead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.</p><p><blockquote>该机构没有对arimoclomol做出批准决定，而是以完整回复信(CRL)的形式要求提供更多信息。这让许多刚接触复杂的药物开发领域并预计会出现大规模轧空的投资者感到震惊。</blockquote></p><p> Many institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.</p><p><blockquote>许多机构投资者对Orphazyme做空，因为其主要候选药物未能达到支持该申请的关键研究的主要终点。Arimoclomol也未能改善患者在FDA特别要求的次要终点上的评分。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> According to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.</p><p><blockquote>据Orphazyme称，该公司需要进一步证实arimoclomol几乎达到的主要终点的有效性。为了让FDA满意，该公司很可能必须进行一项新的关键研究。</blockquote></p><p> Some shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.</p><p><blockquote>一些股东仍然希望欧洲药品管理局不会像FDA那样严格。虽然FDA的欧洲同事过去对罕见疾病的治疗更加宽容，但在产生一些令人信服的临床试验结果之前，arimoclomol可能不会向前推进。</blockquote></p><p> Despite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.</p><p><blockquote>尽管缺乏明确的前进道路，但这家总部位于丹麦的公司仍然拥有相当大的市值，按最近的价格计算超过5亿美元。非理性的预期可能会使其居高不下，但对于Orphazyme的任何临床阶段生物技术来说，这都太高了。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184501396","content_text":"(June 21) Orphazyme rose more than 6% in premarket trading. \n\nWhat happened\nShares of Orphazyme, a clinical-stage biopharmaceutical company, got hammered after the Food and Drug Administration (FDA) refused to approve an application for the company's lead candidate. Investors are now uncertain when the biotech could have an approved product to sell, and pushed the stock 44.4% lower as of 12:12 p.m. EDT on last Friday.\nSo what\nThe FDA began reviewing an application for Orphazyme's lead candidate arimoclomol last September as a potential treatment for a rare but life-threatening disease called Neimann-Pick Disease Type-C (NPC). Earlier this month, shares of Orphazymeshot upmore than 200% in anticipation of a green light that never came.\nInstead of an approval decision for arimoclomol, the agency asked for more information in the form of a complete response letter (CRL). That came as a shock to heaps of investors who were new to the complex world of drug development and were expecting a massiveshort squeeze.\nMany institutional investors were betting against Orphazyme because its lead candidate failed to achieve the primary endpoint in the pivotal study underpinning the application. Arimoclomol also failed to improve patients' scores on a secondary endpoint specifically requested by the FDA.\nNow what\nAccording to Orphazyme, the company needs to further substantiate the validity of the primary endpoint that arimoclomol almost achieved. To satisfy the FDA, the company will most likely have to run a new pivotal study.\nSome shareholders remain hopeful that the European Medicines Agency will be less strict than the FDA. While the FDA's European colleague has been more lenient regarding treatments for rare diseases in the past, arimoclomol probably isn't moving forward until it produces some convincing clinical-trial results.\nDespite lacking a clear path forward, the Denmark-headquartered company still boasts a fairly large market cap in excess of $500 million at recent prices. Irrational expectations could keep it elevated, but this is way too high for anyclinical-stage biotechin Orphazyme's position.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":1668,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166049168,"gmtCreate":1623986347054,"gmtModify":1634024593702,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575604969719218","idStr":"3575604969719218"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166049168","repostId":"2144713861","repostType":4,"isVote":1,"tweetType":1,"viewCount":2929,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166084840,"gmtCreate":1623985566380,"gmtModify":1634024623070,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575604969719218","idStr":"3575604969719218"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166084840","repostId":"2144286417","repostType":4,"isVote":1,"tweetType":1,"viewCount":1368,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163258306,"gmtCreate":1623887070705,"gmtModify":1634026525929,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575604969719218","idStr":"3575604969719218"},"themes":[],"htmlText":"Bad","listText":"Bad","text":"Bad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163258306","repostId":"1199737134","repostType":4,"repost":{"id":"1199737134","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623885157,"share":"https://www.laohu8.com/m/news/1199737134?lang=zh_CN&edition=full","pubTime":"2021-06-17 07:12","market":"us","language":"en","title":"Musk-Touted CureVac Loses 49% of Value After Vaccine Setback<blockquote>马斯克吹捧的CureVac在疫苗受挫后损失了49%的价值</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1199737134","media":"Tiger Newspress","summary":"Company plunges After Covid Shot Falls Short With 47% Efficacy\nEffectiveness is far below that seen ","content":"<p><ul> <li>Company plunges After Covid Shot Falls Short With 47% Efficacy</li> <li>Effectiveness is far below that seen with other mRNA vaccines</li> </ul> CureVac NV shares plunged after a preliminary analysis of a large study muddied by the spread of virus variants found its Covid-19 vaccine was 47% effective, well short of the high bar set by other messenger RNA shots.</p><p><blockquote><ul><li>Covid疫苗疗效达47%后公司股价暴跌</li><li>有效性远低于其他mRNA疫苗</li></ul>CureVac NV股价暴跌，此前对一项因病毒变种传播而陷入混乱的大型研究的初步分析发现，其Covid-19疫苗的有效率为47%，远低于其他信使RNA疫苗设定的高标准。</blockquote></p><p> The interim analysis of data from about 40,000 volunteers included 134 Covid cases, the German company said in a statement. CureVac declined to say how many who got the shot got sick or how many received a placebo. But the results suggest the vaccine works less well for older people than in a younger population, Chief Technology Officer Mariola Fotin-Mleczek said in an interview Wednesday.</p><p><blockquote>这家德国公司在一份声明中表示，对约40,000名志愿者数据的中期分析包括134例Covid病例。CureVac拒绝透露有多少注射疫苗的人生病了，也拒绝透露有多少人接受了安慰剂。但首席技术官Mariola Fotin-Mleczek在周三接受采访时表示，结果表明，该疫苗对老年人的效果不如对年轻人的效果。</blockquote></p><p> Though preliminary, the results throw the future of the vaccine into question as wealthy nations around the world move swiftly to inoculate their populations with shots already available. Still, CureVac will finish its trial and plans to gain approval, Chief Executive Officer Franz-Werner Haas said.</p><p><blockquote>尽管是初步的，但随着世界各地的富裕国家迅速采取行动，用现有的疫苗为其人口接种疫苗，这些结果对疫苗的未来提出了质疑。CureVac首席执行官Franz-Werner Haas表示，尽管如此，CureVac仍将完成试验并计划获得批准。</blockquote></p><p> “There is a huge need for vaccine, and I think we can still make a contribution,” Haas said.</p><p><blockquote>“对疫苗的需求巨大，我认为我们仍然可以做出贡献，”哈斯说。</blockquote></p><p> The company’s shares fell more than 49% in post-market trading after being up 17% this year through Wednesday’s close.</p><p><blockquote>截至周三收盘，该公司股价今年上涨17%，在盘后交易中下跌超过49%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d6ec3f2e05cfbc6c7d87c3fa174f459c\" tg-width=\"1302\" tg-height=\"663\"></p><p><blockquote></blockquote></p><p> In April, Elon Musk tweeted about CureVac, which Tesla Inc. has partnered with on a vaccine printer,saying it “sounds like they’re a few months away from regulatory approval.” He added that “a tidal wave of vaccine is coming this summer.” He later deleted the tweet.</p><p><blockquote>今年4月，Elon Musk在推特上谈到了特斯拉公司与CureVac合作开发疫苗打印机的情况，称“听起来他们距离监管部门批准还有几个月的时间”。他补充说，“今年夏天将迎来一波疫苗浪潮。”他后来删除了这条推文。</blockquote></p><p> The shot could be a boost in the developing world, since it doesn’t require the deep freezing needed for other Covid shots. Partly owned by the German government, CureVac has forged partnerships with Bayer AG,GlaxoSmithKline Plc and the U.K. government aimed at speeding production of its shot and future versions that will target mutated strains.</p><p><blockquote>这种注射可能会促进发展中国家的发展，因为它不需要其他Covid注射所需的深度冷冻。CureVac由德国政府部分拥有，已经与拜耳公司、葛兰素史克公司和英国建立了合作关系。政府旨在加快其疫苗和未来针对突变菌株的版本的生产。</blockquote></p><p> The data comes as the world is at something of a crossroads in the Covid fight, with global infections falling even as outbreaks in places with less access to vaccines serve as a reminder that the pandemic is far from over. The wealthiest countries have taken an outsize share of the more than 2.4 billion shots administered so far.</p><p><blockquote>这些数据发布之际，世界正处于抗击新冠疫情的十字路口，尽管疫苗接种较少的地方爆发疫情，但全球感染人数仍在下降，这提醒人们疫情还远未结束。迄今为止，最富裕的国家在超过24亿次注射中占据了很大份额。</blockquote></p><p> The proliferation of variants in the CureVac trial is testimony to how the pandemic has changed since the first large vaccine clinical trials were run last year.</p><p><blockquote>CureVac试验中变异的扩散证明了自去年进行第一批大型疫苗临床试验以来，疫情发生了怎样的变化。</blockquote></p><p> <b>Genetic Sequencing</b></p><p><blockquote><b>基因测序</b></blockquote></p><p> CureVac’s researchers genetically sequenced 124 of the 134 cases they included in their analysis. Just one of the sequenced cases was due to the original SARS-CoV-2 virus first identified in Wuhan, China. The rest came from a range of variants, including 21% of cases attributable to a new variant called lambda that was first identified in Peru.</p><p><blockquote>CureVac的研究人员对他们纳入分析的134例病例中的124例进行了基因测序。只有一例测序病例是由在我国武汉市首次发现的原始新型冠状病毒病毒引起的。其余的来自一系列变异，包括21%的病例归因于一种名为lambda的新变异，该变异首次在秘鲁发现。</blockquote></p><p> TheWorld Health Organization added lambda to its watchlist as a variant of interest on Monday.</p><p><blockquote>周一，世界卫生组织将lambda作为一种感兴趣的变种添加到其观察名单中。</blockquote></p><p> Some 57% of the Covid cases in the study were due to so-called variants of concern, the four variants that the World Health Organization has deemed the most worrying. Most of these -- about 41% of all the cases -- were due to the alpha variant first observed in the U.K., CureVac said.</p><p><blockquote>研究中约57%的Covid病例是由所谓的令人担忧的变异引起的，这是世界卫生组织认为最令人担忧的四种变异。CureVac说，其中大多数——约占所有病例的41%——是由于首次在英国观察到的阿尔法变异。</blockquote></p><p> That variant is now the most common in the U.S., and other vaccines, including shots from Pfizer Inc. and BioNTech SE as well as Novavax Inc., have shown themselves effective against it. CureVac didn’t release detailed data about how its shot performed against each of the variants.</p><p><blockquote>这种变异现在在美国最常见，其他疫苗，包括辉瑞公司和BioNTech SE以及Novavax公司的疫苗，已经显示出对它有效。CureVac没有发布有关其疫苗对每种变体的表现的详细数据。</blockquote></p><p> <b>Final Readout</b></p><p><blockquote><b>最终读数</b></blockquote></p><p> More details will emerge in the final readout of the study, which will include more than 200 Covid cases and could come within two or three weeks, CureVac said.</p><p><blockquote>CureVac表示，更多细节将在该研究的最终读数中出现，其中将包括200多例Covid病例，可能会在两到三周内公布。</blockquote></p><p> Like the shots from Moderna Inc. and the Pfizer-BioNtech alliance, CureVac’s vaccine relies on mRNA, enlisting the body’s own cells as vaccine factories. Unproven until last year, the technology has now catapulted to the forefront of the global fight against Covid.</p><p><blockquote>与Moderna Inc.和辉瑞-BioNtech联盟的疫苗一样，CureVac的疫苗依赖于mRNA，利用人体自身的细胞作为疫苗工厂。这项技术直到去年才得到证实，但现在已经跃居全球抗击新冠病毒的最前沿。</blockquote></p><p> CureVac’s shot, though, is subtly different than its competitors, because it uses an unmodified form of mRNA.</p><p><blockquote>然而，CureVac的注射与其竞争对手略有不同，因为它使用了未经修饰的mRNA形式。</blockquote></p><p> CureVac has said it plans to supply 300 million vaccine doses this year, enough to immunize 150 million people. Together with partners, it has said it will supply more than 1 billion doses in 2022.</p><p><blockquote>CureVac表示，计划今年供应3亿剂疫苗，足以为1.5亿人提供免疫接种。它与合作伙伴一起表示，将在2022年供应超过10亿剂疫苗。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Musk-Touted CureVac Loses 49% of Value After Vaccine Setback<blockquote>马斯克吹捧的CureVac在疫苗受挫后损失了49%的价值</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMusk-Touted CureVac Loses 49% of Value After Vaccine Setback<blockquote>马斯克吹捧的CureVac在疫苗受挫后损失了49%的价值</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-06-17 07:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><ul> <li>Company plunges After Covid Shot Falls Short With 47% Efficacy</li> <li>Effectiveness is far below that seen with other mRNA vaccines</li> </ul> CureVac NV shares plunged after a preliminary analysis of a large study muddied by the spread of virus variants found its Covid-19 vaccine was 47% effective, well short of the high bar set by other messenger RNA shots.</p><p><blockquote><ul><li>Covid疫苗疗效达47%后公司股价暴跌</li><li>有效性远低于其他mRNA疫苗</li></ul>CureVac NV股价暴跌，此前对一项因病毒变种传播而陷入混乱的大型研究的初步分析发现，其Covid-19疫苗的有效率为47%，远低于其他信使RNA疫苗设定的高标准。</blockquote></p><p> The interim analysis of data from about 40,000 volunteers included 134 Covid cases, the German company said in a statement. CureVac declined to say how many who got the shot got sick or how many received a placebo. But the results suggest the vaccine works less well for older people than in a younger population, Chief Technology Officer Mariola Fotin-Mleczek said in an interview Wednesday.</p><p><blockquote>这家德国公司在一份声明中表示，对约40,000名志愿者数据的中期分析包括134例Covid病例。CureVac拒绝透露有多少注射疫苗的人生病了，也拒绝透露有多少人接受了安慰剂。但首席技术官Mariola Fotin-Mleczek在周三接受采访时表示，结果表明，该疫苗对老年人的效果不如对年轻人的效果。</blockquote></p><p> Though preliminary, the results throw the future of the vaccine into question as wealthy nations around the world move swiftly to inoculate their populations with shots already available. Still, CureVac will finish its trial and plans to gain approval, Chief Executive Officer Franz-Werner Haas said.</p><p><blockquote>尽管是初步的，但随着世界各地的富裕国家迅速采取行动，用现有的疫苗为其人口接种疫苗，这些结果对疫苗的未来提出了质疑。CureVac首席执行官Franz-Werner Haas表示，尽管如此，CureVac仍将完成试验并计划获得批准。</blockquote></p><p> “There is a huge need for vaccine, and I think we can still make a contribution,” Haas said.</p><p><blockquote>“对疫苗的需求巨大，我认为我们仍然可以做出贡献，”哈斯说。</blockquote></p><p> The company’s shares fell more than 49% in post-market trading after being up 17% this year through Wednesday’s close.</p><p><blockquote>截至周三收盘，该公司股价今年上涨17%，在盘后交易中下跌超过49%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d6ec3f2e05cfbc6c7d87c3fa174f459c\" tg-width=\"1302\" tg-height=\"663\"></p><p><blockquote></blockquote></p><p> In April, Elon Musk tweeted about CureVac, which Tesla Inc. has partnered with on a vaccine printer,saying it “sounds like they’re a few months away from regulatory approval.” He added that “a tidal wave of vaccine is coming this summer.” He later deleted the tweet.</p><p><blockquote>今年4月，Elon Musk在推特上谈到了特斯拉公司与CureVac合作开发疫苗打印机的情况，称“听起来他们距离监管部门批准还有几个月的时间”。他补充说，“今年夏天将迎来一波疫苗浪潮。”他后来删除了这条推文。</blockquote></p><p> The shot could be a boost in the developing world, since it doesn’t require the deep freezing needed for other Covid shots. Partly owned by the German government, CureVac has forged partnerships with Bayer AG,GlaxoSmithKline Plc and the U.K. government aimed at speeding production of its shot and future versions that will target mutated strains.</p><p><blockquote>这种注射可能会促进发展中国家的发展，因为它不需要其他Covid注射所需的深度冷冻。CureVac由德国政府部分拥有，已经与拜耳公司、葛兰素史克公司和英国建立了合作关系。政府旨在加快其疫苗和未来针对突变菌株的版本的生产。</blockquote></p><p> The data comes as the world is at something of a crossroads in the Covid fight, with global infections falling even as outbreaks in places with less access to vaccines serve as a reminder that the pandemic is far from over. The wealthiest countries have taken an outsize share of the more than 2.4 billion shots administered so far.</p><p><blockquote>这些数据发布之际，世界正处于抗击新冠疫情的十字路口，尽管疫苗接种较少的地方爆发疫情，但全球感染人数仍在下降，这提醒人们疫情还远未结束。迄今为止，最富裕的国家在超过24亿次注射中占据了很大份额。</blockquote></p><p> The proliferation of variants in the CureVac trial is testimony to how the pandemic has changed since the first large vaccine clinical trials were run last year.</p><p><blockquote>CureVac试验中变异的扩散证明了自去年进行第一批大型疫苗临床试验以来，疫情发生了怎样的变化。</blockquote></p><p> <b>Genetic Sequencing</b></p><p><blockquote><b>基因测序</b></blockquote></p><p> CureVac’s researchers genetically sequenced 124 of the 134 cases they included in their analysis. Just one of the sequenced cases was due to the original SARS-CoV-2 virus first identified in Wuhan, China. The rest came from a range of variants, including 21% of cases attributable to a new variant called lambda that was first identified in Peru.</p><p><blockquote>CureVac的研究人员对他们纳入分析的134例病例中的124例进行了基因测序。只有一例测序病例是由在我国武汉市首次发现的原始新型冠状病毒病毒引起的。其余的来自一系列变异，包括21%的病例归因于一种名为lambda的新变异，该变异首次在秘鲁发现。</blockquote></p><p> TheWorld Health Organization added lambda to its watchlist as a variant of interest on Monday.</p><p><blockquote>周一，世界卫生组织将lambda作为一种感兴趣的变种添加到其观察名单中。</blockquote></p><p> Some 57% of the Covid cases in the study were due to so-called variants of concern, the four variants that the World Health Organization has deemed the most worrying. Most of these -- about 41% of all the cases -- were due to the alpha variant first observed in the U.K., CureVac said.</p><p><blockquote>研究中约57%的Covid病例是由所谓的令人担忧的变异引起的，这是世界卫生组织认为最令人担忧的四种变异。CureVac说，其中大多数——约占所有病例的41%——是由于首次在英国观察到的阿尔法变异。</blockquote></p><p> That variant is now the most common in the U.S., and other vaccines, including shots from Pfizer Inc. and BioNTech SE as well as Novavax Inc., have shown themselves effective against it. CureVac didn’t release detailed data about how its shot performed against each of the variants.</p><p><blockquote>这种变异现在在美国最常见，其他疫苗，包括辉瑞公司和BioNTech SE以及Novavax公司的疫苗，已经显示出对它有效。CureVac没有发布有关其疫苗对每种变体的表现的详细数据。</blockquote></p><p> <b>Final Readout</b></p><p><blockquote><b>最终读数</b></blockquote></p><p> More details will emerge in the final readout of the study, which will include more than 200 Covid cases and could come within two or three weeks, CureVac said.</p><p><blockquote>CureVac表示，更多细节将在该研究的最终读数中出现，其中将包括200多例Covid病例，可能会在两到三周内公布。</blockquote></p><p> Like the shots from Moderna Inc. and the Pfizer-BioNtech alliance, CureVac’s vaccine relies on mRNA, enlisting the body’s own cells as vaccine factories. Unproven until last year, the technology has now catapulted to the forefront of the global fight against Covid.</p><p><blockquote>与Moderna Inc.和辉瑞-BioNtech联盟的疫苗一样，CureVac的疫苗依赖于mRNA，利用人体自身的细胞作为疫苗工厂。这项技术直到去年才得到证实，但现在已经跃居全球抗击新冠病毒的最前沿。</blockquote></p><p> CureVac’s shot, though, is subtly different than its competitors, because it uses an unmodified form of mRNA.</p><p><blockquote>然而，CureVac的注射与其竞争对手略有不同，因为它使用了未经修饰的mRNA形式。</blockquote></p><p> CureVac has said it plans to supply 300 million vaccine doses this year, enough to immunize 150 million people. Together with partners, it has said it will supply more than 1 billion doses in 2022.</p><p><blockquote>CureVac表示，计划今年供应3亿剂疫苗，足以为1.5亿人提供免疫接种。它与合作伙伴一起表示，将在2022年供应超过10亿剂疫苗。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVAC":"CureVac B.V."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199737134","content_text":"Company plunges After Covid Shot Falls Short With 47% Efficacy\nEffectiveness is far below that seen with other mRNA vaccines\n\nCureVac NV shares plunged after a preliminary analysis of a large study muddied by the spread of virus variants found its Covid-19 vaccine was 47% effective, well short of the high bar set by other messenger RNA shots.\nThe interim analysis of data from about 40,000 volunteers included 134 Covid cases, the German company said in a statement. CureVac declined to say how many who got the shot got sick or how many received a placebo. But the results suggest the vaccine works less well for older people than in a younger population, Chief Technology Officer Mariola Fotin-Mleczek said in an interview Wednesday.\nThough preliminary, the results throw the future of the vaccine into question as wealthy nations around the world move swiftly to inoculate their populations with shots already available. Still, CureVac will finish its trial and plans to gain approval, Chief Executive Officer Franz-Werner Haas said.\n“There is a huge need for vaccine, and I think we can still make a contribution,” Haas said.\nThe company’s shares fell more than 49% in post-market trading after being up 17% this year through Wednesday’s close.\n\nIn April, Elon Musk tweeted about CureVac, which Tesla Inc. has partnered with on a vaccine printer,saying it “sounds like they’re a few months away from regulatory approval.” He added that “a tidal wave of vaccine is coming this summer.” He later deleted the tweet.\nThe shot could be a boost in the developing world, since it doesn’t require the deep freezing needed for other Covid shots. Partly owned by the German government, CureVac has forged partnerships with Bayer AG,GlaxoSmithKline Plc and the U.K. government aimed at speeding production of its shot and future versions that will target mutated strains.\nThe data comes as the world is at something of a crossroads in the Covid fight, with global infections falling even as outbreaks in places with less access to vaccines serve as a reminder that the pandemic is far from over. The wealthiest countries have taken an outsize share of the more than 2.4 billion shots administered so far.\nThe proliferation of variants in the CureVac trial is testimony to how the pandemic has changed since the first large vaccine clinical trials were run last year.\nGenetic Sequencing\nCureVac’s researchers genetically sequenced 124 of the 134 cases they included in their analysis. Just one of the sequenced cases was due to the original SARS-CoV-2 virus first identified in Wuhan, China. The rest came from a range of variants, including 21% of cases attributable to a new variant called lambda that was first identified in Peru.\nTheWorld Health Organization added lambda to its watchlist as a variant of interest on Monday.\nSome 57% of the Covid cases in the study were due to so-called variants of concern, the four variants that the World Health Organization has deemed the most worrying. Most of these -- about 41% of all the cases -- were due to the alpha variant first observed in the U.K., CureVac said.\nThat variant is now the most common in the U.S., and other vaccines, including shots from Pfizer Inc. and BioNTech SE as well as Novavax Inc., have shown themselves effective against it. CureVac didn’t release detailed data about how its shot performed against each of the variants.\nFinal Readout\nMore details will emerge in the final readout of the study, which will include more than 200 Covid cases and could come within two or three weeks, CureVac said.\nLike the shots from Moderna Inc. and the Pfizer-BioNtech alliance, CureVac’s vaccine relies on mRNA, enlisting the body’s own cells as vaccine factories. Unproven until last year, the technology has now catapulted to the forefront of the global fight against Covid.\nCureVac’s shot, though, is subtly different than its competitors, because it uses an unmodified form of mRNA.\nCureVac has said it plans to supply 300 million vaccine doses this year, enough to immunize 150 million people. Together with partners, it has said it will supply more than 1 billion doses in 2022.","news_type":1,"symbols_score_info":{"CVAC":0.9}},"isVote":1,"tweetType":1,"viewCount":1756,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163039231,"gmtCreate":1623852908323,"gmtModify":1634027045880,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575604969719218","idStr":"3575604969719218"},"themes":[],"htmlText":"Nice ","listText":"Nice ","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/163039231","repostId":"2143179480","repostType":4,"isVote":1,"tweetType":1,"viewCount":1443,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187219093,"gmtCreate":1623755076912,"gmtModify":1634028973666,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575604969719218","idStr":"3575604969719218"},"themes":[],"htmlText":"Hi everybody ","listText":"Hi everybody ","text":"Hi everybody","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187219093","isVote":1,"tweetType":1,"viewCount":1488,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187291162,"gmtCreate":1623754481656,"gmtModify":1634028988532,"author":{"id":"3575604969719218","authorId":"3575604969719218","name":"yvo92","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575604969719218","idStr":"3575604969719218"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/187291162","repostId":"1122638224","repostType":4,"isVote":1,"tweetType":1,"viewCount":1034,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}